GB2424947A - Methods of assessing a tissue inflammatory response using expression profiles of endothelial cells - Google Patents

Methods of assessing a tissue inflammatory response using expression profiles of endothelial cells Download PDF

Info

Publication number
GB2424947A
GB2424947A GB0615106A GB0615106A GB2424947A GB 2424947 A GB2424947 A GB 2424947A GB 0615106 A GB0615106 A GB 0615106A GB 0615106 A GB0615106 A GB 0615106A GB 2424947 A GB2424947 A GB 2424947A
Authority
GB
United Kingdom
Prior art keywords
methods
inflammatory response
tissue inflammatory
assessing
endothelial cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB0615106A
Other versions
GB0615106D0 (en
Inventor
Steven Kevin Smith
David Stephen Charnock-Jones
Cristin Gregor Print
Nicola Anne Johnson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge University Technical Services Ltd CUTS
Original Assignee
Cambridge University Technical Services Ltd CUTS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge University Technical Services Ltd CUTS filed Critical Cambridge University Technical Services Ltd CUTS
Publication of GB0615106D0 publication Critical patent/GB0615106D0/en
Publication of GB2424947A publication Critical patent/GB2424947A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

The invention provides methods of assessing a tissue inflammatory response, comprising making a quantitative determination of the level of at least five transcripts shown in Table 1, or proteins encoded thereby, in a sample; and comparing the abundance of said transcripts or proteins so determined with the level of said transcript obtained from a control sample. Methods for diagnosis of a condition with which a tissue inflammatory response is associated are also provided, as are gene chip arrays and protein based assays suitable for use in these methods. Assay methods for determining a modulator of a tissue inflammatory response or a condition associated therewith also form part of the invention.

Description

GB 2424947 A continuation (72) cont Cristin Gregor Print Nicola Anne
Johnson (74) Agent and/or Address for Service: Mew burn Ellis LLP York House, 23 Kingsway, LONDON, WC2B 6HP, United Kingdom
GB0615106A 2004-01-16 2005-01-14 Methods of assessing a tissue inflammatory response using expression profiles of endothelial cells Withdrawn GB2424947A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0400976.7A GB0400976D0 (en) 2004-01-16 2004-01-16 Methods of diagnosis
PCT/GB2005/000057 WO2005068655A2 (en) 2004-01-16 2005-01-14 Methods of assessing a tissue inflammatory response using expression profiles of endothelial cells

Publications (2)

Publication Number Publication Date
GB0615106D0 GB0615106D0 (en) 2006-09-06
GB2424947A true GB2424947A (en) 2006-10-11

Family

ID=31726300

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB0400976.7A Ceased GB0400976D0 (en) 2004-01-16 2004-01-16 Methods of diagnosis
GB0615106A Withdrawn GB2424947A (en) 2004-01-16 2005-01-14 Methods of assessing a tissue inflammatory response using expression profiles of endothelial cells

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GBGB0400976.7A Ceased GB0400976D0 (en) 2004-01-16 2004-01-16 Methods of diagnosis

Country Status (10)

Country Link
EP (1) EP1711630A2 (en)
JP (1) JP2007522800A (en)
KR (1) KR20060122927A (en)
CN (1) CN1934274A (en)
AU (1) AU2005205218A1 (en)
CA (1) CA2551677A1 (en)
GB (2) GB0400976D0 (en)
RU (1) RU2006129631A (en)
TW (1) TW200533758A (en)
WO (1) WO2005068655A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7943328B1 (en) 2006-03-03 2011-05-17 Prometheus Laboratories Inc. Method and system for assisting in diagnosing irritable bowel syndrome
DE102006027842B4 (en) * 2006-06-16 2014-07-31 Analytik Jena Ag Method for determining the source of infection in fever of uncertain origin
US20080085524A1 (en) 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
CN101680884A (en) * 2007-05-05 2010-03-24 西安大略大学 methods for the detection of preeclampsia
JP5973419B2 (en) 2010-04-02 2016-08-23 カッパーアールエヌエー，インコーポレイテッド Treatment of CSF3-related diseases by inhibition of natural antisense transcripts against colony stimulating factor 3 (CSF3)
SG10201912361VA (en) 2010-07-27 2020-02-27 Genomic Health Inc Method for using gene expression to determine prognosis of prostate cancer
CN102766679B (en) * 2011-05-04 2015-02-25 上海人类基因组研究中心 Detection method, probe set, and diagnostic kit for predicting postoperation recurrence-free survival of colorectal cancer via gene expression states of two probes
EP2799878A1 (en) * 2013-05-03 2014-11-05 SALION GmbH In vitro method for the early detection of a potential inflammation, in particular associated with rejection of a transplant using kynurenine as a marker.
EP3400953A1 (en) * 2014-12-23 2018-11-14 4D Pharma Research Limited Pirin polypeptide and immune modulation
CN107328941A (en) * 2017-06-24 2017-11-07 梧州市兴能农业科技有限公司 It is a kind of to detect the antibody chip of various kinds of cell adhesion factor simultaneously
CN114452286A (en) * 2021-07-23 2022-05-10 上海交通大学医学院附属新华医院 RAL inhibitors for the prevention and treatment of osteoarthritis

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030036070A1 (en) * 1999-10-21 2003-02-20 Shukti Chakravarti Gene expression profiling of inflammatory bowel disease
EP1319717A1 (en) * 2001-12-11 2003-06-18 Roche Diagnostics GmbH Method for detection of inflammatory processes
US20030124551A1 (en) * 1999-11-03 2003-07-03 Helen Pappa Agents implicated in endometriosis
US20030153731A1 (en) * 1989-04-28 2003-08-14 Hession Catherine A. Endothelial cell-leukocyte adhesion molecules (ELAMs) and molecules involved in leukocyte adhesion (MILAs)
WO2003090694A2 (en) * 2002-04-24 2003-11-06 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring auto immune and chronic inflammatory diseases

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030153731A1 (en) * 1989-04-28 2003-08-14 Hession Catherine A. Endothelial cell-leukocyte adhesion molecules (ELAMs) and molecules involved in leukocyte adhesion (MILAs)
US20030036070A1 (en) * 1999-10-21 2003-02-20 Shukti Chakravarti Gene expression profiling of inflammatory bowel disease
US20030124551A1 (en) * 1999-11-03 2003-07-03 Helen Pappa Agents implicated in endometriosis
EP1319717A1 (en) * 2001-12-11 2003-06-18 Roche Diagnostics GmbH Method for detection of inflammatory processes
WO2003090694A2 (en) * 2002-04-24 2003-11-06 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring auto immune and chronic inflammatory diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Database Genbank GEO, 11 March 2002, "Affymetrix GeneChip Human Genome U95 Version 2 Set HG-U95A", XP002330383; retrieced from WWW.NCBI.MLN.NIH.GOV/GEO, accession No. GPL91 *

Also Published As

Publication number Publication date
WO2005068655A2 (en) 2005-07-28
RU2006129631A (en) 2008-02-27
WO2005068655A3 (en) 2005-11-17
KR20060122927A (en) 2006-11-30
TW200533758A (en) 2005-10-16
GB0400976D0 (en) 2004-02-18
JP2007522800A (en) 2007-08-16
AU2005205218A1 (en) 2005-07-28
GB0615106D0 (en) 2006-09-06
CA2551677A1 (en) 2005-07-28
CN1934274A (en) 2007-03-21
EP1711630A2 (en) 2006-10-18

Similar Documents

Publication Publication Date Title
GB2424947A (en) Methods of assessing a tissue inflammatory response using expression profiles of endothelial cells
JP2008505638A5 (en)
WO2006099421A3 (en) Methods and compositions for evaluating graft survival in a solid organ transplant recipient
WO2006012507A3 (en) Methods and compositions for risk stratification
NO20043259L (en) Binding proteins as biosensors
NO20074389L (en) Determination of responders to chemotherapy
WO2006073976A3 (en) Compositions, methods, and kits for enhancing protein expression, solubility and isolation
CA2797854A1 (en) Predictive markers useful in the treatment of fragile x syndrome (fxs)
GB2412913A (en) Compositions and methods for preserving rna in biological samples
WO2004080175A3 (en) Scaffold for cell growth and differentiation
WO2006050071A3 (en) Ceramic laminate structures
WO2005118872A3 (en) Methods and kits for diagnosing or monitoring autoimmune and chronic inflammatory diseases
NO20053177L (en) Methods and Compositions for Characterization of Redox Reagent System Enzyme.
WO2003034025A3 (en) Methods and reagents for improved cell-based assays
WO2005033275A3 (en) Methods for altering hematopoietic progenitor cell adhesion, differentiation, and migration
WO2008025961A3 (en) Method of diagnosis
WO2006060739A3 (en) Ubiquitin ligase assays and related reagents
Schultz et al. Prediction of recurrence in Ta urothelial cell carcinoma by real‐time quantitative PCR analysis: a microarray validation study
WO2004078783A3 (en) Enzymes involved in apoptosis
SE9900615D0 (en) Method and kit for early cancer prediction
WO2003099107A3 (en) Methods and kits for the detection of renal cell carcinoma in a biological fluid of a patient
WO2001050130A3 (en) Screening methods for compounds useful in the treatment of polycystic kidney disease
WO2008025963A3 (en) Method of diagnosis
WO2007127002A3 (en) Protein markers of responsiveness to type iii receptor tyrosine kinase inhibitors
WO2004065959A3 (en) Kinases and gpcrs involved in apoptosis

Legal Events

Date Code Title Description
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1092508

Country of ref document: HK

WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1092508

Country of ref document: HK